2023年4月11日

美國加州雷德伍德城紅木市,加利福尼亞州,4月11日,2023(全球通訊社)——Gynesonics®, inc .)婦女的醫療保健公司專注於子宮肌瘤微創的發展解決方案,3月初宣布,跳過Baldino被任命為總裁兼首席執行官的角色。Baldino先生也將作為董事會成員,成功克裏斯托弗•歐文斯。Gynesonics也高興地宣布,該公司已經關閉了25美元的重大融資幫助進一步推動增長和采用奏鳴曲®係統。Baldino先生擁有超過35年的醫療經驗,私人企業和大型上市公司。Gynesonics之前,他擔任了八年總統和首席執行官EndoGastric解決方案(EGS)公司,在那裏他幫助EGS變成一個領袖的內腔治療胃食管反流病(GERD)。Baldino EGS之前,美國的總統被成像有限公司,一個領導者在胃腸診斷和成像Covidien於2014年以8.6億美元的價格收購。鑒於成像之前,他在雅培公司享有傑出的26年職業生涯,一個全球多元化的醫療保健公司,他在那裏建立了一個優秀的記錄一致和高性能的成功商業領導角色在糖尿病護理、診斷,公司醫療產品,醫院產品(現在Hospira),衛生係統,專業的產品。Baldino先生也是ACell的董事會主席,再生醫學Inc .公司開發和商業化傷口管理醫療器械和外科軟組織修複。他曾在ACell董事會從2015年到2021年銷售Integra健康科學,價值高達4億美元。“我很興奮加入Gynesonics團隊在公司的商業進化的這個關鍵時刻,“Baldino先生說。 “The Sonata System offers proven clinical outcomes to provide women with a minimally invasive, incisionless treatment alternative for symptomatic uterine fibroids. Additionally, the $25M investment in our company will give us added fuel to accelerate adoption and drive future growth.” Commenting on the appointment of Mr. Baldino, Dave Pacitti, Chairman of the Board, Gynesonics said, “Skip is a proven leader who has demonstrated the ability to consistently scale businesses. Through his experiences at Abbott, Given Imaging, and EndoGastric Solutions, he has a deep understanding of the medical device industry and will help guide Gynesonics in its mission to advance minimally invasive treatment options in women’s health across the globe.” “We would also like to express our deepest gratitude to Chris Owens,” added Mr. Pacitti. “As CEO for the past nine years, Chris provided Gynesonics with critically important leadership through the pivotal clinical trial, regulatory clearances, and initial product launch which established a strong foundation of adoption and revenue growth.” “I am extremely proud to have led Gynesonics through significant transformations over the past nine years,” said Chris Owens. “The Sonata System is changing the lives of women with symptomatic fibroids across the globe. I look forward to Skip continuing the rapid rate of growth we established while bringing his more than 35 years of exceptional proven performance and experience to the company.” About the Sonata System The Sonata System is intended for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. Common Side Effects include bleeding, spotting, cramping, post-ablation inflammatory symptoms, and/or discharge. There are potential risks with this treatment such as skin burn and infection. Women who are pregnant, have a pelvic infection, are known to have gynecologic cancer, or have intratubal implants for sterilization should not have this procedure. The Sonata System is CE marked and is approved for sale in the European Union, the United Kingdom, and the United States. For more information on Sonata, please visit us at www.sonatasystem.com . About Uterine Fibroids Fibroids are benign growths in or around the uterus. They are common and most women develop them during childbearing age. In the U.S., around 70% of white women and more than 80% of black women will have uterine fibroids before the age of 50. Problematic fibroids can range in size from a raisin to a grapefruit, and symptoms may worsen over time if fibroids are left untreated. 20% to 50% of women with fibroids are symptomatic and each year in the U.S., more than 2 million women undergo treatment for uterine fibroids. Women with symptomatic fibroids may present one or more of the following: · Abnormal uterine bleeding/menorrhagia